Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial

Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial

Roberta Caputo,1 Alessandra Fabi,2,3 Emanuela Romagnoli,4 Editta Baldini,5 Donatella Grasso,6 Nicola Fenderico,6 Andrea Michelotti7 1Dipartimento di Senologia, Istituto Nazionale Tumori Fondazione Pascale, IRCCS, Naples, Italy; 2Dipartimento di Oncologia Medica, Istituto Nazionale Tumori Regina Elen...

Full description

Bibliographic Details
Main Authors: Caputo R, Fabi A, Romagnoli E, Baldini E, Grasso D, Fenderico N, Michelotti A
Format: Article
Language:English
Published: Dove Medical Press 2022-10-01
Series:Breast Cancer: Targets and Therapy
Subjects:
cdk4/6 inhibitor
targeted therapy
male breast cancer
progression-free survival
case report
Online Access:https://www.dovepress.com/ribociclib-plus-letrozole-in-italian-male-patients-with-hormone-recept-peer-reviewed-fulltext-article-BCTT

Internet

https://www.dovepress.com/ribociclib-plus-letrozole-in-italian-male-patients-with-hormone-recept-peer-reviewed-fulltext-article-BCTT

Similar Items